Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Barclays analyst Gena Wang maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $467.00.

Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Biotechnology Market OverviewThe Biotechnology Market report delivers crucial insights into the market's growth trajectory ...

Carle Heath is stepping up its specialty care options this month for foot and ankle health at its Eureka hospital.

Highlights,Several firms have recently revised their price targets for Ingredion.,Stephens lowered its target price for the ...

Highlights,Increased institutional ownership in Vertex Inc. with notable transactions recorded.,Strong year-over-year revenue ...

The tech world is buzzing with exciting developments and innovations every day, let's find out what's new has been introduced ...

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...